News stories about Cerus (NASDAQ:CERS) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerus earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.8710475887329 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Cerus from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a research report on Tuesday, July 24th. BidaskClub raised shares of Cerus from a “hold” rating to a “buy” rating in a research note on Wednesday, August 29th. Cantor Fitzgerald reissued a “reduce” rating and set a $9.00 target price on shares of Cerus in a research note on Friday, July 20th. Cowen set a $10.00 target price on shares of Cerus and gave the company a “buy” rating in a research note on Friday, August 3rd. Finally, ValuEngine raised shares of Cerus from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 1st. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Cerus presently has an average rating of “Buy” and an average target price of $8.13.

Shares of NASDAQ:CERS opened at $7.27 on Monday. The firm has a market cap of $972.83 million, a price-to-earnings ratio of -12.98 and a beta of 1.60. Cerus has a 12-month low of $2.43 and a 12-month high of $8.05. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.03 and a quick ratio of 4.57.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $15.42 million during the quarter, compared to analyst estimates of $13.58 million. Cerus had a negative net margin of 76.37% and a negative return on equity of 82.60%. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.16) EPS. equities analysts forecast that Cerus will post -0.43 EPS for the current fiscal year.

In related news, CFO Kevin Dennis Green sold 50,000 shares of Cerus stock in a transaction on Tuesday, August 28th. The shares were sold at an average price of $7.50, for a total value of $375,000.00. Following the completion of the sale, the chief financial officer now owns 110,825 shares of the company’s stock, valued at approximately $831,187.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Richard J. Benjamin sold 35,416 shares of Cerus stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $7.20, for a total transaction of $254,995.20. Following the completion of the sale, the insider now directly owns 35,416 shares of the company’s stock, valued at approximately $254,995.20. The disclosure for this sale can be found here. Insiders have sold a total of 88,199 shares of company stock valued at $649,365 in the last three months. Company insiders own 6.80% of the company’s stock.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Further Reading: Google Finance Portfolio Tips and Tricks

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.